心血管2008年进展.ppt

* * * * Patients will be randomized to amlodipine/benazepril 5/20 mg or benazepril/HCTZ 20/12.5 mg, and will have their doses force-titrated to standard maintenance doses of amlodipine/benazepril 5/40 mg, and benazepril/HCTZ 40/12.5 mg during the first 2 months. The doses can be increased to 10/40 mg or 40/25 mg, respectively, and after 3 months other antihypertensive agents (excluding the drug classes involved in the primary treatments) may be added to achieve blood pressure 140/90 mmHg (130/80 mmHg for patients with diabetes or renal insufficiency). Investigators will be strongly encouraged to reach target blood pressure in all patients. Patients will be seen at 3 months, 6 months, and thereafter at 6-month intervals until the end of the trial.1 (Jamerson et al. Am J Hypertens. 2004;17: A) ACCOMPLISH is an event-driven trial: patients will be treated until 1,642 primary cardiovascular events have been reported. It is estimated this will take approximately 5 years, including the 18 months of recruitment. 1. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17:793–801. * * * * * * * * * * * CP1328717 Cha, YM KK 09-23-2008 * 左室射血分数保留的心衰研究 Year 1: HR 0.69 (0.47,1.01), p=0.055 Year 2: HR 0.92 (0.70,1.21), p=0.545 1Y: 46 vs 65 events 2Y: 107 vs 100 HR 0.95 (0.86-1.06), p=0.60 I-PRESERVE PEP-CHF 发生死亡及住院患者发生心衰的时间 舒张期心力衰竭 综合分析现有的三项应用RAS阻滞剂治疗舒张期心力衰竭的研究（CHARM-Preserved，PEP-CHF与I-Preserve）可以认为，两种类型的心力衰竭在发病机制方面可能具有本质区别，RAS系统激活在舒张期心力衰竭的病理生理过程中可能并非关键环节，因此应用ARB或ACEI类药物难以有效改善患者预后。 Company Logo 5.心律失常领域—历尽严冬仍无春? 自从20年前CAST试验（Cardiac?Arrhythmia?Suppression?Trial）使Ic类药物受到重挫以后，抗心律失常药物研究领域一直处于漫漫长冬。在此期间，III类抗心律失常药物日渐受到重视。正因如此，国内外学者一直高度关注着关于新型抗心律失常药物Dronedarone的各项研究结果。 Company Lo